Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

British Journal of Cancer

Volumn 108, Issue 5, 2013, Pages 1052-1060

  Miles, D W ^a   De Haas, S L ^b   Dirix, L Y ^c   Romieu, G ^d   Chan, A ^e   Pivot, X ^f   Tomczak, P ^g   Provencher, L ^h   Cortes J ⁱ   Delmar, P R ^b   Scherer, S J ^j  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c SINT AUGUSTINUS HOSPITAL   (Belgium)

^d Anticancer Center   (France)

^e Mount Hospital   (Australia)

^f UNIVERSITY HOSPITAL OF BESANÇON   (France)

^g Klinika Onkologii Oddzial Chemioterapii   (Poland)

^h Centre des Maladies du Sein Deschênes Fabia   (Canada)

ⁱ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^j GENENTECH INC   (United States)

more..

Author keywords

bevacizumab; biomarker; metastatic breast cancer; predictive; vascular endothelial growth factor; VEGF

Indexed keywords

BEVACIZUMAB; DOCETAXEL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; PLACEBO; TUMOR MARKER; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DNA DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PHASE 3 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; TAXOIDS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84875412193     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.69     Document Type: Article

References (26)

1. Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS (2011) RIBBON-2: a randomized, double-blind, placebo-controlled, phaseIII trial evaluating the efficacy and safety of bevacizumab in combinationwith chemotherapy for second-line treatment of human epidermalgrowth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 29:4286-4293.
2. Carmeliet P, Pallaud C, Deurloo RJ, Bubuteishvili-Pacaud L, Henschel V, DentR, Bell R, Mackey J, Scherer SJ, Cameron D (2012) Plasma (p) VEGF-Aand VEGFR-2 biomarker (BM) results from the BEATRICE phase III trialof bevacizumab (BEV) in triple-negative early breast cancer (BC) . CancerRes 72: 321s (abstract P3-06-34) .
3. Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH (2008) Cell adhesionmolecules, vascular endothelial growth factor, and basic fibroblast growthfactor in patients with non-small cell lung cancer treated withchemotherapy with or without bevacizumab-an Eastern CooperativeOncology Group Study. Clin Cancer Res 14: 1407-1412.
4. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N. AVOREN Trial investigators (2007) Bevacizumab plus interferon alfa-2a for treatment of metastaticrenal cell carcinoma: a randomised, double-blind phase III trial. Lancet370: 2103-2111.
5. Ferrara N (2004) Vascular endothelial growth factor as a target for anticancertherapy. Oncologist 9 (Suppl 1) : 2-10.
6. Foernzler D, Delmar P, Kockx M, Cassidy J, Saltz L, Scherer S (2010) Tumortissue based biomarker analysis in NO16966 a randomized phase III studyof first-line bevacizumab in combination with oxaliplatin-basedchemotherapy in patients with mCRC. ASCO GI Cancers Symposium, 22-24 January 2010, Orlando, FL, USA, (abstract 374) .
7. Gianni L, Chan A, Mansutti M, Pivot X, Greil R, Provencher L, Prot S, MooreN, Scherer SJ, Pallaud C (2012) Biomarker (BM) results from the phase IIIAVEREL trial of 1st-line bevacizumab (BV) , trastuzumab (H) \+docetaxel (T) for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC) . Ann Oncol 23 (suppl 9) : ix531 (abstract 1657P) .
8. Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL (2009) Independentreview of E2100: a phase III trial of bevacizumab plus paclitaxel versuspaclitaxel in women with metastatic breast cancer. J Clin Oncol 27:4966-4972.
9. Hegde PS, Jubb AM, Chen D, Li NF, Meng G, Bernaards C, Elliott R, SchererS, Chen DS (2013) Predictive impact of circulating vascular endothelialgrowth factor in 4 phase III trials evaluating bevacizumab. Clin CancerRes; e-pub ahead of print 4 February 2013.
10. Jayson GC, de Haas S, Delmar P, Miles DW, Shah MA, Van Cutsem E, Carmeliet P, Hegde P, Wild N, Scherer SJ (2011) Evaluation of plasmaVEGFA as a potential predictive pan-tumour biomarker for bevacizumab.European Multidisciplinary Cancer Congress, 23-27 September 2011, Stockholm, Sweden, (abstract 804) .
11. Jubb AM, Miller KD, Rugo HS, Harris AL, Chen D, Reimann JD, CobleighMA, Schmidt M, Langmuir VK, Hillan KJ, Chen DS, Koeppen H (2011) Impact of exploratory biomarkers on the treatment effect of bevacizumabin metastatic breast cancer. Clin Cancer Res 17: 372-381.
12. Lambrechts D, Claes B, Delmar P, Reumers J, Mazzone M, Yesilyurt BT, Devlieger R, Verslype C, Tejpar S, Wildiers H, de Haas S, Carmeliet P, Scherer SJ, Van Cutsem E (2012) VEGF pathway genetic variants asbiomarkers of treatment outcome with bevacizumab: an analysis ofdata from the AViTA and AVOREN randomised trials. Lancet Oncol 13:724-733.
13. Lambrechts D, Delmar P, Miles DW, Leighl N, Saltz L, Escudier B, VanCutsem E, Scherer SJ, Carmeliet P, de Haas S (2011a) Single nucleotidepolymorphism analysis and outcome in advanced-stage cancer patientstreated with bevacizumab. European Multidisciplinary Cancer Congress, 23-27 September 2011, Stockholm, Sweden, (abstract 1414) .
14. Lambrechts D, Miles DW, Leighl N, Saltz L, Escudier B, Van Cutsem E, Bansal AT, Scherer SJ, Carmeliet P, de Haas S (2011b) Genetic markers inrelation to bevacizumab-induced hypertension. European MultidisciplinaryCancer Congress, 23-27 September 2011, Stockholm, Sweden, (abstract1412) .
15. Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P, Delozier T, SohnJH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G (2010a) Phase III study ofbevacizumab plus docetaxel compared with placebo plus docetaxel for thefirst-line treatment of human epidermal growth factor receptor 2-negativemetastatic breast cancer. J Clin Oncol 28: 3239-3247.
16. Miles D, Romieu G, Diéras V, Chen D, Duenne A, O'Shaughnessy J (2010b) Meta-analysis of patients previously treated with taxanes from threerandomised trials of bevacizumab and first-line chemotherapy astreatment for metastatic breast cancer. Ann Oncol 21 (Suppl 8) : 97 (abstract 279PD) .
17. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK (2011) Bevacizumabin combination with chemotherapy as first-line therapy in advancedgastric cancer: a randomized, double-blind, placebo-controlled phase IIIstudy. J Clin Oncol 29: 3968-3976.
18. O'Shaughnessy J, Dieras V, Glaspy J, Brufsky A, Miller K, Miles D, KoralewskiP, Phan S, Bhattacharya S (2009) Comparison of subgroup analyses of PFSfrom three phase III studies of bevacizumab in combination withchemotherapy in patients with HER2-negative metastatic breast cancer (MBC) . Cancer Res 69 (suppl) : 512s (abstract 207) .
19. O'Shaughnessy J, Miles D, Gray RJ, Dieras V, Perez EA, Zon R, Cortes J, ZhouX, Phan S, Miller K (2010a) A meta-analysis of overall survival data fromthree trials of bevacizumab and first-line chemotherapy as treatment forpatients with metastatic breast cancer. J Clin Oncol 28 (15S) : abstract 1005.
20. O'Shaughnessy J, Romieu G, Dieras V, Byrtek M, Duenne A-A, Miles D (2010b) Meta-analysis of patients with triple-negative breast cancer fromthree randomised trials of first-line bevacizumab and chemotherapytreatment for metastatic breast cancer. Cancer Res 70 (suppl 24) : 452s (abstract P6-12-03) .
21. Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, PerezEA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trialof chemotherapy with or without bevacizumab for first-line treatment ofhuman epidermal growth factor receptor 2-negative locally recurrent ormetastatic breast cancer. J Clin Oncol 29: 1252-1260.
22. Saltz LB, Clarke S, D?́az-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy asfirst-line therapy in metastatic colorectal cancer: a randomized phase IIIstudy. J Clin Oncol 26: 2013-2019.
23. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, FlockhartDA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD. ECOG 2100 (2008) Association ofvascular endothelial growth factor and vascular endothelial growth factorreceptor-2 genetic polymorphisms with outcome in a trial of paclitaxelcompared with paclitaxel plus bevacizumab in advanced breast cancer:ECOG 2100. J Clin Oncol 26: 4672-4678.
24. Van Cutsem E, de Haas S, Kang YK, Ohtsu A, Tebbutt NC, Ming Xu J, PengYong W, Langer B, Delmar P, Scherer SJ, Shah MA (2012) Bevacizumab incombination with chemotherapy as first-line therapy in advanced gastriccancer: a biomarker evaluation from the AVAGAST randomized phase IIItrial. J Clin Oncol 30: 2119-2127.
25. Van Cutsem E, Jayson G, Dive C, Dilba P, de Haas S, Wild N, Delmar P, Scherer SJ (2011) Analysis of blood plasma factors in the AVITA phase IIIrandomized study of bevacizumab (bev) with gemcitabine-erlotinib (GE) inpatients (pts) with metastatic pancreatic cancer (mPC) . EuropeanMultidisciplinary Cancer Congress, 23-27 September 2011, Stockholm, Sweden, (abstract 803) .
26. Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van LaethemJL, Verslype C, Scheithauer W, Shang A, Cosaert J, Moore MJ (2009) Phase III trial of bevacizumab in combination with gemcitabine anderlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27:2231-2237.